Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Market Access
  • CMS Extends Medicare’s Short-Term Bridge Program for GLP-1 Obesity Drug Coverage
  • Market Access

CMS Extends Medicare’s Short-Term Bridge Program for GLP-1 Obesity Drug Coverage

KFF Medicare

Extending the short-term GLP-1 Bridge program is good news for eligible Medicare beneficiaries because it provides the certainty of obesity drug coverage at a $50 copay for a longer duration, but fede

Market AccessMetabolic & GLP-1Read full story

pharminent April 23, 2026 (Last updated: April 24, 2026)

KFF Medicare

Extending the short-term GLP-1 Bridge program is good news for eligible Medicare beneficiaries because it provides the certainty of obesity drug coverage at a $50 copay for a longer duration, but fede

Market AccessMetabolic & GLP-1Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Drugmaker AbbVie chooses North Carolina for $1.4B manufacturing campus
Next: FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program

Related Stories

  • Market Access

NICE aims to cut funding for Amgen lung cancer drug Lumykras

pharminent July 9, 2026
  • Market Access

UK, pharma industry pilot rapid access routes for medicines

pharminent July 5, 2026
  • Market Access

Medicare GLP-1 Bridge Launches July 1 With $50 Copays

pharminent July 3, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.